First 60 Days of the Trump Administration: Food and Agriculture Policy
A Brief Primer on Tariffs Under the Trump Administration
Navigating the Inflation Reduction Act: Insights on Brownfield Energy Community Credits - Energy Law Insights
Growing the Solar and Storage Landscape With Mike Hall, Anza Renewables - Battery + Storage Podcast
Navigating Clean Hydrogen Tax Credits: Insights and Implications - Energy Law Insights
Podcast — Drug Pricing: How the Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry
Podcast — Drug Pricing: How Are Payers Responding to the IRA?
Inflation Reduction Act Tax Trends Begin to Take Shape
Wiley's 10 Key Trade Developments: The CHIPS Act and Inflation Reduction Act (IRA)
Wiley’s Top 10 Trade Developments: Buy America Requirements
4 Key Takeaways | Harnessing the Inflation Reduction Act: Driving Investments in Renewable Energy and Carbon Reduction
The Capacity Crunch, Part Three: Unpacking the Power of the IRA: The Potential Game-Changing Opportunities for Utilities - Energy Law Insights
The Capacity Crunch, Part Two: Public Utilities, Resource Planning & Deployment, and the IRA - Energy Law Insights
The Capacity Crunch, Part One: Reliability and Decarbonization in the Short Term - Energy Law Insights
Analyzing the Impact of the IRA on Energy Storage — Battery + Storage Podcast
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 171: Laura Gunter, President of the NC Life Sciences Organization
Domesticating the Battery Supply Chain With ENTEK and KORE Power — Battery + Storage Podcast
Financing Future Trends in Storage With George Koutsonicolis, SOLIC Capital - Battery + Storage Podcast
ESG Essentials: What You Need To Know Now - Episode 15 - Climate Week NYC
Inflation Reduction Act’s Drug Price Negotiation Provisions – What Now? – Diagnosing Health Care Podcast
The U.S. Environmental Protection Agency (EPA) has long navigated the complex intersection of science, law, policy, and public trust. Under the Trump Administration, EPA faces renewed scrutiny. The Administration seeks...more
On April 15, 2025, President Trump signed the Lowering Drug Prices by Once Again Putting Americans First Executive Order (Executive Order). The Executive Order revives and expands several pharmaceutical pricing and payment...more
“While President Donald Trump’s love of tariffs is often attributed to his desire for leverage in negotiations, the ones he seeks to use to reshore manufacturing are inherently intended to be non-negotiable."...more
On April 15, 2025, President Trump signed an executive order titled “Lowering Drug Prices by Once Again Putting Americans First.” The order includes various provisions that are relevant to the pharmaceutical industry,...more
As an industry at the frontline of navigating a shifting policy backdrop under the new Trump administration, pre-imposition of “Independence Day” Tariffs, energy was experiencing a growth in interest from private equity...more
On April 15, 2025, President Trump issued an executive order titled “Lowering Drug Prices by Once Again Putting Americans First.” The order reaffirms and seeks to expand on policy initiatives introduced during the president’s...more
On April 15, President Donald Trump signed an Executive Order (EO) titled “Lowering Drug Prices by Once Again Putting Americans First,” outlining a renewed policy agenda to reduce prescription drug costs. The EO is framed as...more
Key points include access to medicines in medicare is reduced as the IRA is implemented; fewer drugs are covered on Medicare Part D formularies in 2025 relative to 2024; medicines for serious conditions with high unmet needs...more
The nuclear energy industry continues to gain momentum and has a strong outlook for 2025 and beyond. This positive forecast is buoyed by support from both major political parties, increased demand, technical advancements, and...more
The Energy Marketers of America (formerly, Petroleum Marketers Association of America) (“EMA”) submitted April 10th comments to the Internal Revenue Service (“IRS”) addressing its: …notice of intent to propose regulations...more
The Centers for Medicare & Medicaid Services (CMS) released on April 4, 2025, the final rule for contract year (CY) 2026 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit...more
The Trump Administration is leveraging the U.S. Department of Energy's Loan Programs Office (LPO) as a strategic tool to catalyze private sector investment in energy infrastructure. This approach aims to enhance U.S....more
This past week, the Trump administration put its first major stamp on the Medicare Advantage (MA) program. The Centers for Medicare & Medicaid Services (CMS) released two final regulatory documents related to MA: - The...more
The IRS recently released an updated Form 4255, Certain Credit Recapture, Excessive Payments, and Penalties, which is used to report the amount due for certain credit recaptures, excessive payments, excessive credit transfers...more
Artificial intelligence is revolutionizing life science R&D (particularly in the realm of drug discovery) and challenging the traditional "human inventorship" requirement for U.S. patents. Recent guidance from the USPTO...more
The Latham drug pricing and market access team invites you to read this digest of recent developments on healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....more
No legislation has garnered more attention in the life sciences industry in recent past than the so-called Drug Price Negotiation Program of the Inflation Reduction Act (the "Program"). ...more
After a flurry of actions in February, March seemed relatively calm by comparison, though there was plenty to track and unpack as the month progressed. All eyes are on what House Republicans will end up cutting from the...more
Since taking office on January 20, President Donald Trump has used his executive authority to make an unprecedented number of major policy changes. This includes dramatic shifts in the legal and regulatory landscapes,...more
The electric vehicle (EV) industry is facing a mix of challenges and opportunities as the Trump Administration’s recent policies and tariff announcements take effect in the market. In its first three months, the Trump...more
Evaluating current formulary access for the 25 drugs selected for Drug Price Negotiation in Medicare Part D shows several selected drugs have higher co-pays in 2025 relative to 2024 - Introduction - The Inflation Reduction...more
In this episode of Holland & Knight's "The Eyes on Washington" podcast series, Agriculture & Food Policy Team Leaders Peter Tabor and Liz Craddock provide a comprehensive overview of food and agriculture policy updates from...more
A group of four Democratic AGs sued the EPA and Citibank, N.A., as a financial agent for the federal government, alleging that they wrongfully denied the states access to funds appropriated by Congress for clean-energy...more
On January 3, 2025, the US Department of the Treasury released final Treasury regulations applicable to the hydrogen production tax credit under Section 45V and the investment tax credit for hydrogen production facilities...more
What role will solar, wind and storage technologies play in addressing the pending “energy emergency” in the United States, and how is the industry responding to heightened policy uncertainty stemming from the new federal...more